Lesion Dosimetry for [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer
Journal of Nuclear Medicine · 2023-11 · 64 (11) · 1779-1787
DOI: 10.2967/jnumed.123.265763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 31.08.2023. Verfasst von Milan Grkovski und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; grkovskm@mkscc.org bodeil@mkscc.org. Hauptthemen laut MEDLINE: Radiosurgery, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
A single-institution prospective pilot clinical trial was performed to demonstrate the feasibility of combining [177Lu]Lu-PSMA-617 radiopharmaceutical therapy (RPT) with stereotactic body radiotherapy (SBRT) for the treatment of oligometastatic castration-sensitive prostate cancer.
Methods
Six patients with 9 prostate-specific membrane antigen (PSMA)-positive oligometastases received 2 cycles of [177Lu]Lu-PSMA-617 RPT followed by SBRT. After the first intravenous infusion of [177Lu]Lu-PSMA-617 (7.46 ± 0.15 GBq), patients underwent SPECT/CT at 3.2 ± 0.5, 23.9 ± 0.4, and 87.4 ± 12.0 h. Voxel-based dosimetry was performed with calibration factors (11.7 counts per second/MBq) and recovery coefficients derived from in-house phantom experiments. Lesions were segmented on baseline PSMA PET/CT (50% SUVmax). After a second cycle of [177Lu]Lu-PSMA-617 (44 ± 3 d; 7.50 ± 0.10 GBq) and an interim PSMA PET/CT scan, SBRT (27 Gy in 3 fractions) was delivered to all PSMA-avid oligometastatic sites, followed by post-PSMA PET/CT. RPT and SBRT voxelwise dose maps were scaled (α/β = 3 Gy; repair half-time, 1.5 h) to calculate the biologically effective dose (BED).
Results
All patients completed the combination therapy without complications. No grade 3+ toxicities were noted. The median of the lesion SUVmax as measured on PSMA PET was 16.8 (interquartile range [IQR], 11.6) (baseline), 6.2 (IQR, 2.7) (interim), and 2.9 (IQR, 1.4) (post). PET-derived lesion volumes were 0.4-1.7 cm3 The median lesion-absorbed dose (AD) from the first cycle of [177Lu]Lu-PSMA-617 RPT (ADRPT) was 27.7 Gy (range, 8.3-58.2 Gy; corresponding to 3.7 Gy/GBq, range, 1.1-7.7 Gy/GBq), whereas the median lesion AD from SBRT was 28.1 Gy (range, 26.7-28.8 Gy). Spearman rank correlation, ρ, was 0.90 between the baseline lesion PET SUVmax and SPECT SUVmax (P = 0.005), 0.74 (P = 0.046) between the baseline PET SUVmax and the lesion ADRPT, and -0.81 (P = 0.022) between the lesion ADRPT and the percent change in PET SUVmax (baseline to interim). The median for the lesion BED from RPT and SBRT was 159 Gy (range, 124-219 Gy). ρ between the BED from RPT and SBRT and the percent change in PET SUVmax (baseline to post) was -0.88 (P = 0.007). Two cycles of [177Lu]Lu-PSMA-617 RPT contributed approximately 40% to the maximum BED from RPT and SBRT.
Conclusion
Lesional dosimetry in patients with oligometastatic castration-sensitive prostate cancer undergoing [177Lu]Lu-PSMA-617 RPT followed by SBRT is feasible. Combined RPT and SBRT may provide an efficient method to maximize the delivery of meaningful doses to oligometastatic disease while addressing potential microscopic disease reservoirs and limiting the dose exposure to normal tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; grkovskm@mkscc.org bodeil@mkscc.org.
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Varian Medical Systems Inc., Palo Alto, California; and.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York grkovskm@mkscc.org bodeil@mkscc.org.
Förderung
- NCI NIH HHS
Zitieren
APA
Grkovski, M., O'Donoghue, J. A., Imber, B. S., Andl, G., Tu, C., Lafontaine, D., Schwartz, J., Thor, M., Zelefsky, M. J., Humm, J. L., & Bodei, L. (2023). Lesion Dosimetry for [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer. Journal of Nuclear Medicine, 64(11), 1779-1787. https://doi.org/10.2967/jnumed.123.265763
Vancouver
Grkovski M, O'Donoghue JA, Imber BS, Andl G, Tu C, Lafontaine D, et al. Lesion Dosimetry for [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer. Journal of Nuclear Medicine. 2023;64(11):1779-1787. doi:10.2967/jnumed.123.265763
BibTeX
@article{Grkovski2023,
author = {Grkovski, Milan and O'Donoghue, Joseph A and Imber, Brandon S and Andl, George and Tu, Cheng and Lafontaine, Daniel and Schwartz, Jazmin and Thor, Maria and Zelefsky, Michael J and Humm, John L and Bodei, Lisa},
title = {Lesion Dosimetry for [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {11},
pages = {1779--1787},
doi = {10.2967/jnumed.123.265763}
}
EUVIMED